Belite Bio (BLTE) Total Liabilities (2021 - 2026)
Belite Bio (BLTE) posted quarterly Total Liabilities of $15.5 million for Q1 2026, up 152.54% year-over-year from $6.1 million in Q1 2025, and up 53.75% quarter-over-quarter from $10.1 million in Q4 2025.
Belite Bio (BLTE) Total Liabilities (2021 - 2026) Analysis & Trends
Belite Bio's Total Liabilities history runs 6 years deep, the most recent figure standing at $15.5 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 152.54% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $15.5 million (up 152.54% YoY), while the FY2025 annual figure was $10.1 million, up 59.56% from the prior year.
- Total Liabilities for Q1 2026 stood at $15.5 million, up from $10.1 million in the prior quarter.
- The five-year high for Total Liabilities was $15.5 million in Q1 2026, with the low at $2.8 million in Q4 2022.
- The 5-year median for Total Liabilities is $4.9 million (2023), against an average of $6.2 million.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities decreased 24.63% in 2024, then jumped 152.54% in 2026.
- Belite Bio's Total Liabilities stood at $2.8 million in 2022, then surged by 51.91% to $4.2 million in 2023, then jumped by 49.87% to $6.3 million in 2024, then jumped by 59.56% to $10.1 million in 2025, then surged by 53.75% to $15.5 million in 2026.
- Business Quant data shows BLTE's Total Liabilities at $15.5 million in Q1 2026, $10.1 million in Q4 2025, and $8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 15.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.48 Mn |
| Dec 31, 2025 | 10.07 Mn |
| Sep 30, 2025 | 8.31 Mn |
| Jun 30, 2025 | 6.52 Mn |
| Mar 31, 2025 | 6.13 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Sep 30, 2024 | 3.62 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 4.68 Mn |
| Dec 31, 2023 | 4.21 Mn |
| Sep 30, 2023 | 4.80 Mn |
| Jun 30, 2023 | 4.98 Mn |
| Mar 31, 2023 | 4.65 Mn |
| Dec 31, 2022 | 2.77 Mn |
| Dec 31, 2021 | 1.64 Mn |